Toxicity profile of polyradiomodification therapy used in the combination treatment for rectal cancer

Objective: to analyze the spectrum of toxic reactions associated with various polyradiomodification regimens used in the combination therapy for rectal cancer.

Materials and methods. We have conducted a retrospective analysis of the data from a prospectively collected database. We included patients with stages сT2–3N0M0 and сT2–3N1–2M0 resectable rectal cancer. Polyradiomodification regimens included a course of radiotherapy (5 × 5 Gy) with the following radiomodifiers: rectal administration of a biopolymer composition containing metronidazole (MZ)  at a dose of 10 g/m² (twice), intracavitary local microwave hyperthermia (three times on days 3–5) and oral capecitabine (Cap).

Results. The study included 241 participants. Toxic reactions were observed in less than 33.2 % of patients receiving polyradiomodification as a part of combination therapy. The most common adverse events were gastrointestinal toxicity and neurotoxicity, diagnosed in 28.6 % and 17.4 % of cases respectively. The frequency of toxic reactions was significantly higher in patients receiving Cap14 + MZ regimen than in those receiving Cap5 + MZ regimen (p = 0.0038). However, the inclusion of microwave hyperthermia in both Cap5 and Cap14 therapeutic regimens had no impact on the frequency of toxic reactions (44.2 and 31.5 % respectively, p = 0.146). The proportion of patients with grade III gastrointestinal toxicity did not significantly vary across the groups (p = 0.16).

Conclusion. The course of polyradiomodification included into the combination therapy for rectal cancer has an acceptable toxicity profile and can be used to improve long-term outcomes of combination treatment for rectal cancer.

1. Heald R.J. Total mesorectal exsicion (TME). Acta Chir Iugosl 1999;47 (4 Suppl 1):17–8. PMID: 11432236.

2. Rahbari N.N., Elbers H., Askoxylakis V. et al. Neoadjuvant radiotherapy for rectal cancer: meta-analysis of randomized controlled trials. Ann Surg Oncol 2013;20(13):4169–82. PMID: 24002536. DOI: 10.1245/s10434-013-3198-9.

3. Barsukov Yu.A. Combination and complex therapy for rectal cancer. Moscow, 2011. 97 p. (In Russ.).

4. Therapeutic radiology: guideline for physicians. Ed. by A.F. Tsyb, Yu.S. Mardynskiy. Moscow: MK LLC, 2010. 552 p. (In Russ.).

5. Yarmolenko S.P. Polyradiomodification as a new approach to increase the effectiveness of radiotherapy for cancer. In: Radiomodifiers in radiotherapy. Obninsk, 1982. Pp. 126–127. (In Russ.).

6. Barsukov Yu.A. et al. “Method of treatment for rectal cancer (radiotherapy, rectal administration of a biopolymer composition containing metronidazole, 5 days of capecitabine)”. Patent for invention RUS No. 2311909, dated 2007. (In Russ.).

7. Barsukov Yu.A. et al. “Method of treatment for rectal cancer (neoadjuvant radiotherapy, microwave hyperthermia, rectal administration of a biopolymer composition containing metronidazole, 5 days of capecitabine)”. Patent for invention RUS No. 2367489, dated 2009. (In Russ.).

8. Barsukov Yu.A. et al. “Method of treatment for rectal cancer (neoadjuvant radiotherapy, microwave hyperthermia, rectal administration of a biopolymer composition containing metronidazole, 2 weeks of capecitabine)”. Patent for invention RUS No. 2477641, dated 2013. (In Russ.).

9. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28, 2009 (v. 4.03: June 14, 2010). U.S. Department Of Health And Human Services, National Institutes of Health, National Cancer Institute.

10. Collette L., Bosset J.F., den Dulk M. et al. Patients with curative resection of cT3–4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007;25(28):4379–86. PMID: 17906203. DOI: 10.1200/JCO.2007.11.9685.

11. Bosset J.F., Calais G., Daban A. et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur J Cancer 2004;40(2):219–24. PMID: 14728936.